Helyx Industries S.p.A., a healthcare biotech company, develops, produces, and markets invitro diagnostic medical devices in Italy. The company through its Sagitta, a proprietary reagent platform designed to support deep multiplexing qPCR; and stable multiplex reagents. It also offers HYRIS bAPP, a software interface for managing and instructing Hyris system operations, as well as HYRIS bCUBE, an IVDR device compliant, designed according to industrial quality and operational safety criteria; and HYRIS bGATE, a gateway device that allows laboratories to integrate data and results. In addition, the company's platforms also comprise Hyris System, a proprietary technology, offers revolutionary solutions to laboratories and healthcare professionals, enabling the decentralization of genetics, as well as offers agrifood and nutraceuticals catalogue, and development and OEM services. Further, it develops customized NGS panels, advanced sequencing solutions and optimized bioinformatics pipelines to support clinical and research applications; and provides various tests and reagents for sexually transmitted diseases and HPV. The company was formerly known as Ulisse Biomed S.p.A. and change its name to Helyx Industries S.p.A. in December 2025. Helyx Industries S.p.A. was founded in 2015 and is based in Udine, Italy.…
HLX prezzo e grafico azione — MIL:HLX
Helyx Industries (BIT: HLX) is listed on Borsa Italiana, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 22 employees.
The shares were at 0.6800 EUR on 20 November 2026, down 13.9% over 52 weeks. Its 52-week range is 0.5600 EUR to 0.9180 EUR: the price is 25.9% below the high and 21.4% above the low.
Its market capitalisation is 17.98M EUR.
Helyx Industries reports return on equity of -21.7%, an operating margin of -96.3% and revenue up 293.6% year over year.
It holds more cash than debt, a net cash position of 714.62K EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock; their mean price target of 1.187 EUR is 74.5% above the current price.
No upcoming events tracked.